Keywords: Xention, Grunenthal, Research, Pain drugs, Ion channel drug discovery
Xention and Grunenthal in research collaboration focussing on novel pain drugs
Article | 16 February 2011
Cambridge, UK-based biopharmaceutical company Xention, specializing in the discovery and development of ion channel-modulating drugs, has entered into a research ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
